Novartis has announced plans to acquire Anthos Therapeutics, a biopharmaceutical company specializing in cardiovascular treatments, for an upfront payment of $925 million. The agreement also includes potential additional payments of up to $2.15 billion, contingent upon the achievement of specific development milestones.
This strategic move aims to enhance Novartis's late-stage cardiovascular pipeline.
Anthos Therapeutics, established in 2019 through a collaboration between Blackstone Life Sciences and Novartis, focuses on developing innovative therapies for cardiovascular diseases.
Their lead product candidate, abelacimab, is an investigational monoclonal antibody targeting Factor XI and XIa, which are key components in the blood coagulation process. Abelacimab is currently undergoing Phase III clinical trials for various indications, including the prevention of stroke and systemic embolism in patients with atrial fibrillation, as well as the treatment of cancer-associated thrombosis.
The acquisition aligns with Novartis's strategy to focus on five core therapeutic areas, one of which is cardiovascular diseases. By integrating abelacimab into its portfolio, Novartis aims to address significant unmet medical needs in thromboembolic disorders and strengthen its position in the cardiovascular market.
The transaction is expected to close in the first half of 2025, subject to customary closing conditions and regulatory approvals. Upon completion, Novartis plans to leverage its global development and commercialization capabilities to advance abelacimab and potentially offer a new therapeutic option for patients at risk of thromboembolic events.
This acquisition underscores Novartis's commitment to investing in innovative medicines and expanding its pipeline in areas of high unmet medical need. By acquiring Anthos Therapeutics, Novartis aims to bring forward a promising therapy that could significantly impact the treatment landscape for patients with cardiovascular diseases.
コメント